The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

Merck ( NYSE: MRK) has confirmed a deal worth around $10 billion to acquire Verona Pharma ( NASDAQ: VRNA ), a biotech firm ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Merck, through a subsidiary, will acquire Verona Pharma for a total transaction value of approximately $10 billion.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma giant’s pipeline and portfolio of cardio-pulmonary disease treatments.